{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}],"title":"Seroma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"title":"Wound Infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Wound Dehiscence"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Our primary outcome was the incidence of post-surgical complications, to include wound dehiscence, infection, and seroma.","groups":[{"description":"Received dalteparin 5000 units daily postop, patients with metastatic disease.","id":"OG000","title":"Interventional (Dalteparin, Metastatic)"},{"description":"Received dalteparin 5000 units daily postop, patients with primary sarcomas.","id":"OG001","title":"Interventional (Dalteparin, Sarcoma)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"4 weeks after surgery","title":"Number of Participants With Post-operative Wound Complications","type":"PRIMARY","unitOfMeasure":"Participants"}